Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 929-931, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Friedman, K. J.
Right arrow Articles by Silverman, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Friedman, K. J.
Right arrow Articles by Silverman, L. M.
Related Collections
Right arrow Molecular Diagnostics and Genetics
Right arrow Pediatric Clinical Chemistry
(Clinical Chemistry. 1999;45:929-931.)
© 1999 American Association for Clinical Chemistry, Inc.

Editorial

Cystic Fibrosis Syndrome: A New Paradigm for Inherited Disorders and Implications for Molecular Diagnostics

Kenneth J. Friedman and Lawrence M. Silvermana

Department of Pathology, and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514
a Author for correspondence. Fax 919-966-6351; e-mail lmsmol.dhl1@mail.unch.unc.edu.

In this issue, Castaldo et al. (1) describe the use of denaturing gradient gel electrophoresis to scan the CFTR gene in cystic fibrosis (CF) patients from Southern Italy who were negative for the common CF mutations. As expected, rare mutations were found, five of which were useful in population screening. These findings are particularly important for laboratories in Italy and in areas with families of Italian descent.

Advanced molecular techniques provide a double-edged sword because they often detect sequence changes whose deleterious natures are by no means established. In the CFTR gene, such variants may cause classic CF, elicit atypical phenotypes with similarities to CF, or have no consequence to health.

Among recent letters in the New England Journal of Medicine on mild phenotypic variants of CF (2)(3)(4), one suggested that "the diagnosis of cystic fibrosis is too nebulous to preserve in clinical practice and that perhaps, as is the case with Cushing's disease and syndrome, we need to have both a cystic fibrosis `disease'. . . and a cystic fibrosis `syndrome' (which would include the pancreatic manifestations, congenital bilateral absence of the vas deferens, or lesser pulmonary manifestations)" (3). As improved mutation detection technologies enter the clinical laboratory and identify rare CFTR mutations, laboratorians and clinicians must be cognizant of the changing nature of genotype-phenotype associations.

The severity of the pancreatic and hepatic features of CF is highly variable. The gastrointestinal presentations endured by CF patients take many forms (5). The majority of patients (85–90%) experience pancreatic exocrine insufficiency. Those who retain pancreatic exocrine function (10–15%) typically carry at least one of the CFTR gene mutations that have been associated with residual function. Other CF patients have impaired endocrine insulin production associated with diabetes (10–15% of patients) . . . [Full Text of this Article]


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.